X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES DISHMAN PHARMA JUBILANT LIFE SCIENCES/
DISHMAN PHARMA
 
P/E (TTM) x 15.4 25.1 61.6% View Chart
P/BV x 4.6 3.3 136.2% View Chart
Dividend Yield % 0.4 0.7 60.1%  

Financials

 JUBILANT LIFE SCIENCES   DISHMAN PHARMA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
DISHMAN PHARMA
Mar-16
JUBILANT LIFE SCIENCES/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs187374 49.9%   
Low Rs65129 50.5%   
Sales per share (Unadj.) Rs364.3197.8 184.2%  
Earnings per share (Unadj.) Rs6.821.2 32.3%  
Cash flow per share (Unadj.) Rs24.534.7 70.6%  
Dividends per share (Unadj.) Rs3.002.00 150.0%  
Dividend yield (eoy) %2.40.8 299.7%  
Book value per share (Unadj.) Rs164.9179.9 91.7%  
Shares outstanding (eoy) m159.2880.69 197.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.31.3 27.2%   
Avg P/E ratio x18.411.9 155.0%  
P/CF ratio (eoy) x5.17.2 70.9%  
Price / Book Value ratio x0.81.4 54.6%  
Dividend payout %43.89.4 464.6%   
Avg Mkt Cap Rs m20,06120,306 98.8%   
No. of employees `0006.20.8 746.1%   
Total wages/salary Rs m11,0525,355 206.4%   
Avg. sales/employee Rs Th9,383.019,252.7 48.7%   
Avg. wages/employee Rs Th1,786.96,459.5 27.7%   
Avg. net profit/employee Rs Th176.32,064.1 8.5%   
INCOME DATA
Net Sales Rs m58,03415,961 363.6%  
Other income Rs m191265 71.8%   
Total revenues Rs m58,22416,226 358.8%   
Gross profit Rs m5,7864,103 141.0%  
Depreciation Rs m2,8121,091 257.8%   
Interest Rs m3,237944 342.8%   
Profit before tax Rs m-722,334 -3.1%   
Minority Interest Rs m-2860-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m2,1450-   
Tax Rs m696624 111.7%   
Profit after tax Rs m1,0901,711 63.7%  
Gross profit margin %10.025.7 38.8%  
Effective tax rate %-965.926.7 -3,614.5%   
Net profit margin %1.910.7 17.5%  
BALANCE SHEET DATA
Current assets Rs m29,28011,018 265.8%   
Current liabilities Rs m38,9129,517 408.9%   
Net working cap to sales %-16.69.4 -176.5%  
Current ratio x0.81.2 65.0%  
Inventory Days Days84110 76.4%  
Debtors Days Days5135 145.5%  
Net fixed assets Rs m55,71216,304 341.7%   
Share capital Rs m155161 95.7%   
"Free" reserves Rs m20,96812,907 162.5%   
Net worth Rs m26,26514,516 180.9%   
Long term debt Rs m17,1694,189 409.8%   
Total assets Rs m88,60629,805 297.3%  
Interest coverage x1.03.5 28.2%   
Debt to equity ratio x0.70.3 226.5%  
Sales to assets ratio x0.70.5 122.3%   
Return on assets %4.98.9 54.8%  
Return on equity %4.211.8 35.2%  
Return on capital %11.617.5 66.0%  
Exports to sales %37.824.8 152.5%   
Imports to sales %16.53.7 441.3%   
Exports (fob) Rs m21,9333,956 554.4%   
Imports (cif) Rs m9,567596 1,604.4%   
Fx inflow Rs m22,0044,952 444.4%   
Fx outflow Rs m11,749697 1,686.1%   
Net fx Rs m10,2554,255 241.0%   
CASH FLOW
From Operations Rs m8,0262,786 288.0%  
From Investments Rs m-1,744-1,529 114.1%  
From Financial Activity Rs m-4,447-941 472.6%  
Net Cashflow Rs m1,834316 579.8%  

Share Holding

Indian Promoters % 45.6 61.4 74.3%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 3.7 235.1%  
FIIs % 21.2 12.7 166.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 22.1 95.5%  
Shareholders   23,815 46,261 51.5%  
Pledged promoter(s) holding % 15.9 35.8 44.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  ASTRAZENECA PHARMA  BIOCON LTD  

Compare JUBILANT LIFE SCIENCES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Brexit Deal; Key Q2FY19 Results & Top Stocks in Focus Today(Pre-Open)

On Thursday, Indian share markets ended marginally higher led by bank stocks and finance stocks. At the closing bell, the BSE Sensex ended up by 119 points.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY19); Net Profit Up 67.2% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 67.2% YoY). Sales on the other hand came in at Rs 23 bn (up 38.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY19); Net Profit Up 39.4% (Quarterly Result Update)

Jul 31, 2018 | Updated on Jul 31, 2018

For the quarter ended June 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 39.4% YoY). Sales on the other hand came in at Rs 21 bn (up 30.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY18); Net Profit Up 1.4% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 1.4% YoY). Sales on the other hand came in at Rs 23 bn (up 37.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

Which Equity Mutual Funds to Buy Now?(Outside View)

Nov 13, 2018

PersonalFN explains that in falling markets investing in equity mutual funds can be beneficial in long run by choosing the right equity mutual fund scheme.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Nov 15, 2018 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 8-QTR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS